Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Oxford Biomedica plc is a leading contract development and manufacturing organization (CDMO) specializing in cell and gene therapy viral vectors. Founded in 1996 and headquartered in Oxford, UK, the company pioneers advanced bioprocessing for lentiviral, adeno-associated virus (AAV), adenovirus, and other vector types, supporting clients from early-stage development to commercial GMP manufacturing. Its proprietary technologies, including the LentiVector® platform and TetraVecta™ 4th generation lentiviral system, enable scalable production of therapies targeting cancers, Parkinson’s, CNS disorders, and ocular conditions. Operating a global network with facilities in the UK, France, and the US, Oxford Biomedica plc serves pharmaceutical and biotech partners in biotechnology, clinical vaccines, and bioprocessing sectors. With over 30 years of experience, robust quality systems, and regulatory expertise, it facilitates life-changing therapies, evidenced by numerous successful audits, GMP batches, and products approved in multiple countries.
Select a linked metric to explore its chart.